Latest Middle East News

SRJ Technologies reported a remarkable 178% increase in Q4 FY24 cash receipts, driven by strong contract activity and strategic partnerships, including a key Middle East market entry. Despite some project delays, the company remains confident in its growth trajectory for FY25.

Advanced Health Intelligence Ltd has locked in a USD$4 million convertible note facility with UAE-based KOR Investments LLC, aiming to raise up to AUD$10 million to fuel its MENA expansion and reduce debt.

NSX Limited reports a $1.6 million cash injection from ISXFEU, completes the ClearPay joint venture sale, and reduces operational costs in its 2Q25 activities report, while facing delays in share issuance approval.

NH3 Clean Energy has made significant strides in its WAH2 Project, finalising critical commercial agreements and progressing technical work ahead of Front End Engineering and Design (FEED) entry scheduled for Q1 2025. The company also completed a capital raise to support these developments.

ClearVue Technologies has secured key manufacturing and distribution agreements across the Middle East, China, and the UK, while acquiring ROOTS Sustainable Agricultural Technologies to bolster its net zero ag-tech solutions.

Unith Ltd has reported its strongest quarterly revenue in two years, driven by its B2C subscription division and strategic partnerships, while advancing its Digital Human technology and expanding into new markets.

Urbanise.com Limited reports a modest revenue increase in H1 FY2025 despite a Q2 license revenue dip, driven by customer churn and a contract dispute. The company achieves positive cash flow and advances banking partnerships to bolster its strata management platform.

OncoSil Medical has secured new distribution agreements across key international markets and achieved critical regulatory milestones, while raising $8 million to fuel its growth in pancreatic cancer treatment.

Opyl Limited's Q2 FY25 update reveals robust progress through key partnerships, a new AI Biotech Fund launch, and strengthened financial footing, positioning the company for expanded influence in clinical trial optimisation.

Starpharma reports encouraging FDA feedback on its DEP® SN38 candidate for ovarian cancer and prepares for product launches in Saudi Arabia and UAE, supported by a solid $20.3 million cash position.

ReNerve Limited has reported a remarkable 260% increase in quarterly sales following its successful IPO, alongside strategic distribution deals in Hong Kong and the Middle East. The company is poised for further growth with upcoming clinical data and product developments.

Fitzroy River Corporation's latest quarterly report reveals a dip in royalty income but highlights progress on major silver and gold projects, alongside strategic moves in energy royalties.